Fosamax Exposure Linked to Osteonecrosis of the Jaw: Mechanisms and Evidence

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Targeted Risk Awareness

The legacy of general health and science information has long provided a foundation for public understanding of medical conditions and treatment options. Within this context, discussions of bone health and pharmaceutical interventions have been standard, emphasizing patient education and informed decision-making. As this informational heritage evolves, a natural progression emerges toward examining specific therapeutic exposures and their potential implications. The transition from broad health awareness to focused occupational concern begins with recognizing that certain medications, while beneficial for their intended purposes, may introduce considerations relevant to workplace safety and clinical monitoring. In particular, the shift toward mass production environments necessitates a closer look at how exposure to specific compounds, such as bisphosphonates like Fosamax, intersects with occupational health protocols. This pivot does not require detailed mechanistic explanations but rather acknowledges that the legacy of general health communication now supports a more targeted inquiry into exposure risks. The concern for occupational settings arises from the need to identify and manage potential adverse outcomes associated with chronic or high-level contact, moving beyond general patient advisories to address the specific vulnerabilities of workers in manufacturing or healthcare environments. Thus, the bridge from legacy heritage to occupational exposure concern is built on the principle of extending established health literacy into specialized risk assessment frameworks.

Bridging to Occupational Exposure Concerns

Building on the foundation of general health education, this article now focuses specifically on Fosamax (alendronate) and its association with osteonecrosis of the jaw (ONJ). Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with a serious adverse effect known as osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. Osteonecrosis of the jaw can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanisms Linking Fosamax to Osteonecrosis of the Jaw

The mechanistic pathways linking Fosamax to ONJ involve the drug's pharmacology as a bisphosphonate. Bisphosphonates like alendronate inhibit bone resorption by suppressing osteoclast activity, which can lead to reduced bone turnover. In the jawbone, this suppression may impair the normal remodeling processes necessary for healing after dental procedures or in response to infection. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents has provided information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). Research using estrogen-deficient rat models has examined the effects of bisphosphonate (alendronate) treatment on jawbone properties, including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077). These studies suggest that bisphosphonate treatment alters the mechanical and structural characteristics of jawbone, potentially contributing to ONJ pathogenesis.

Evidence of Causation and Risk Factors

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under "Warnings and Precautions" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and identifies known risk factors. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label also states that in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), which may complicate the assessment of causation. Causation-related considerations for affected patients involve evaluating the temporal relationship between Fosamax exposure and ONJ onset. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal relationship in some individuals. However, ONJ can also occur spontaneously in the absence of bisphosphonate use, and the presence of other risk factors such as cancer, chemotherapy, or dental disease must be considered when assessing individual cases. The timeline between exposure and documented harm can vary widely. While some patients develop symptoms within days of starting Fosamax, others may not experience ONJ until after months or years of use. The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients at low risk for fracture, the prescribing information suggests considering drug discontinuation after 3 to 5 years of use, as the optimal duration of use has not been determined (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This recommendation reflects concerns about long-term adverse effects, including ONJ. In summary, the evidence indicates that Fosamax exposure is linked to osteonecrosis of the jaw through mechanisms involving suppressed bone turnover and altered jawbone properties. Warnings in the prescribing information address this risk, but the variable onset and presence of confounding factors require careful case-by-case evaluation for causation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ) and how is it related to Fosamax?

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the maxillofacial region. It has been reported in patients taking bisphosphonates, including Fosamax (alendronate). ONJ can occur spontaneously but is generally associated with tooth extraction or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate exposure.

How does Fosamax cause osteonecrosis of the jaw?

Fosamax inhibits bone resorption by suppressing osteoclast activity, leading to reduced bone turnover. In the jawbone, this suppression may impair normal remodeling processes necessary for healing after dental procedures or infection. Studies have shown that bisphosphonate treatment alters the mechanical and structural characteristics of jawbone, potentially contributing to ONJ pathogenesis (https://pubmed.ncbi.nlm.nih.gov/40345077).

What is the typical timeline between starting Fosamax and developing ONJ?

The time to onset of ONJ symptoms can vary from one day to several months after starting Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief after stopping the drug, and some have recurrence upon rechallenge. The risk may increase with longer duration of use.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.